pyrazines has been researched along with Endometrial Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, H; Liu, Y; Lu, L; Meng, W; Qing, Y; Shen, Y; Xu, J; Zhang, B | 1 |
| Hu, HY; Lu, L; Shen, Y | 1 |
| Bertoni, F; Catapano, CV; Colombo, N; Del Conte, G; Gadducci, A; Hess, D; Katsaros, D; Mancari, R; Marsoni, S; Parma, G; Rinaldi, A; Scambia, G; Sessa, C; van de Velde, H; Vitali, A | 1 |
| Bergadà, L; Dolcet, X; Llombart-Cussac, A; Martí, RM; Matias-Guiu, X; Sorolla, A; Valls, J; Yeramian, A | 1 |
| Dolcet, X; Encinas, M; Eritja, N; Llobet, D; Llombart-Cussac, A; Marti, RM; Matias-Guiu, X; Schoenenberger, JA; Sorolla, A; Yeramian, A | 1 |
1 trial(s) available for pyrazines and Endometrial Neoplasms
| Article | Year |
|---|---|
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CA-125 Antigen; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2012 |
4 other study(ies) available for pyrazines and Endometrial Neoplasms
| Article | Year |
|---|---|
Bortezomib induces apoptosis of endometrial cancer cells through microRNA-17-5p by targeting p21.
Topics: Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; MicroRNAs; Molecular Sequence Data; Proteasome Endopeptidase Complex; Protein Binding; Pyrazines; RNA, Small Interfering | 2013 |
[Mechanism of bortezomib in inducing apoptosis and improving chemosensitivity of Ishikawa cells].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cell Line, Tumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; Inhibitory Concentration 50; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species | 2010 |
Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endometrial Neoplasms; Endometrium; Female; Humans; Indoles; NF-kappa B; Pyrazines; Pyrroles; Sunitinib | 2012 |
Antioxidants block proteasome inhibitor function in endometrial carcinoma cells.
Topics: Antioxidants; Antipyrine; Apoptosis; Ascorbic Acid; Blotting, Western; Boronic Acids; Bortezomib; Butylated Hydroxyanisole; Caspase 3; Caspase 9; Caspase Inhibitors; Cell Line, Tumor; Cell Survival; Coumarins; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Edaravone; Endometrial Neoplasms; Ergothioneine; Female; Humans; Leupeptins; Oligopeptides; Proteasome Inhibitors; Pyrazines; Ubiquitin; Vitamin E; Vitamins | 2008 |